Abstract:Rotavirus (RV) causes the loss of numerous children’s lives worldwide each year, and this burden is particularly heavy in low- and lower-middle-income countries where access to healthcare is limited. RV epidemiology exhibits a diverse range of genotypes, which can vary in prevalence and impact across different regions. The human genotypes that are most commonly recognized are G1P[8], G2P[4], G3P[8], G4P[8], G8P[8], G9P[8], and G12P[8]. The diversity of rotavirus genotypes presents a challenge in understanding its global distribution and developing effective vaccines. Oral, live-attenuated rotavirus vaccines have undergone evaluation in various contexts, encompassing both low-income and high-income populations, demonstrating their safety and effectiveness. Rotavirus vaccines have been introduced and implemented in over 120 countries, offering an opportunity to assess their effectiveness in diverse settings. However, these vaccines were less effective in areas with more rotavirus-related deaths and lower economic status compared to wealthier regions with fewer rotavirus-related deaths. Despite their lower efficacy, rotavirus vaccines significantly decrease the occurrence of diarrheal diseases and related mortality. They also prove to be cost-effective in regions with a high burden of such diseases. Regularly evaluating the impact, influence, and cost-effectiveness of rotavirus vaccines, especially the newly approved ones for worldwide use, is essential for deciding if these vaccines should be introduced in countries. This is especially important in places with limited resources to determine if a switch to a different vaccine is necessary. Future research in rotavirus epidemiology should focus on a comprehensive understanding of genotype diversity and its implications for vaccine effectiveness. It is crucial to monitor shifts in genotype prevalence and their association with disease severity, especially in high-risk populations. Policymakers should invest in robust surveillance systems to monitor rotavirus genotypes. This data can guide vaccine development and public health interventions. International collaboration and data sharing are vital to understand genotype diversity on a global scale and facilitate the development of more effective vaccines.

New vaccines to boost child care in developing countries.

Protection of staphylococci ingested by macrophages from the bactericidal action of rifampin

Rotavirus vaccines: progress and new developments

Rotavirus Vaccines: Effectiveness, Safety, and Future Directions

Follow-Up of Osteochondral Plug Transfers in a Goat Model

The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review

Current status of rotavirus vaccines

Global rotavirus vaccine introductions and coverage: 2006 - 2016

Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years

Rotavirus in developing countries: molecular diversity, epidemiological insights, and strategies for effective vaccination

Parenteral, non-live rotavirus vaccine: recent history and future perspective

Global Illness and Deaths Caused by Rotavirus Disease in Children

Implementation of Rotavirus Surveillance and Vaccine Introduction - World Health Organization African Region, 2007-2016

Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea

In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis

Tracheoesophageal trauma.

Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus

Thermodynamics of urban population flows.

A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact

Human hypoxic ventilatory response with blood dopamine content under intermittent hypoxic training.

Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors